|
Affiliation |
Hospital Department of Pharmacy |
Graduating School 【 display / non-display 】
-
-2002.03
Tohoku Pharmaceutical University Faculty of Pharmaceutical Science Graduated
Graduate School 【 display / non-display 】
-
-2010.03
Tohoku Pharmaceutical University Graduate School, Division of Pharmaceutical Sciences Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2023.12-Now
Akita University Hospital Department of Pharmacy Professor
Research Areas 【 display / non-display 】
-
Life Science / Clinical pharmacy
Research Achievements 【 display / non-display 】
-
Delayed decrease in voriconazole concentration after resolution of inflammation in a patient with invasive pulmonary aspergillosis: a case report.
Haruka Igarashi, Hayato Yokota, Ayano Saito, Yumiko Akamine, Naoto Takahashi, Masafumi Kikuchi
Journal of pharmaceutical health care and sciences 2026.05 [Refereed]
Research paper (journal)
BACKGROUND: Voriconazole (VRCZ) is an effective treatment for pulmonary aspergillosis. Active infectious disease leads to a reduction in cytochrome P450 activity, resulting in increased VRCZ concentrations. However, the impact of VRCZ dose reduction during the severe inflammatory state on VRCZ concentrations after the resolution of inflammation is not yet fully understood. Here, we report the time-course changes in VRCZ blood concentrations after inflammation in a patient with invasive pulmonary aspergillosis. CASE PRESENTATION: A man in his 60s receiving oral VRCZ tablets at 400 mg/day for invasive pulmonary aspergillosis developed marked inflammation due to bacterial pneumonia and influenza virus infection. C-reactive protein (CRP) levels increased to a peak of 35.54 mg/dL, with a concomitant elevation in the VRCZ trough concentration to 4.7 µg/mL. Following dose reduction to VRCZ 300 mg/day, the trough concentration decreased to 1.1 µg/mL on day 11 after dose reduction, while CRP declined to 4.78 mg/dL after antibiotic therapy. VRCZ was continued at the same dose. However, four weeks after CRP levels had stabilized, the VRCZ concentration decreased to 0.6 µg/mL. After re-escalation of VRCZ to 400 mg/day, the trough concentration returned to the effective therapeutic range of 1.1 µg/mL. CONCLUSIONS: After infection is controlled, VRCZ concentrations may decrease to levels below the therapeutic range. Following VRCZ dose reduction during a high inflammatory state, reassessment of trough concentrations after improvement of inflammation may be useful to prevent excessive decreases in VRCZ concentrations.
-
Clinical association among tacrolimus dose requirement,<i> CYP3A</i> genotypes, and the concentrations of urinary endogenous CYP3A biomarkers in lung transplant recipients: A cross-sectional study
Masaki Kumondai, Masafumi Kikuchi, Atsushi Mizuguchi, Ayaka Yagi, Nagomi Hayashi, Yoshinori Okada, Yu Sato, Toshihiro Sato, Masamitsu Maekawa, Nariyasu Mano
HELIYON 12 ( 9 ) 2026.05 [Refereed]
Research paper (journal)
-
Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study.
Yayoi Fukushi, Kazuma Fujita, Yumiko Akamine, Haruka Igarashi, Katsuya Sasaki, Koji Fukuda, Hiroyuki Shibata, Masafumi Kikuchi
Journal of pharmaceutical health care and sciences 2026.02
Research paper (journal)
-
Development and Clinical Application of a Simultaneous Liquid Chromatography-Tandem Mass Spectrometry Method for Patients with Graft-versus-Host Disease to Quantify the Plasma Concentrations of Ruxolitinib and Posaconazole.
Masaki Kumondai, Nagomi Hayashi, Yu Sato, Daisuke Kobayashi, Ayaka Otsuki, Yugo Ueki, Yasushi Onishi, Taku Tsukamoto, Kohei Yoshikawa, Yoshihiro Hayakawa, Yuji Sato, Toshihiro Sato, Mayumi Sato, Masafumi Kikuchi, Masamitsu Maekawa, Nariyasu Mano
Biological & pharmaceutical bulletin 49 ( 2 ) 301 - 309 2026
Research paper (journal)
Graft-versus-host disease (GVHD) is a clinically significant problem with high mortality that is gradually increasing. Ruxolitinib (RUX) is the only drug used for steroid-refractory GVHD treatment and is thereby crucial. Therapeutic drug monitoring of RUX may be effective because of the relationship between the plasma RUX concentration and treatment outcomes. Posaconazole (PCZ) has also been the recent focus of combined treatment with RUX owing to its pharmacokinetics. We established a simultaneous LC-tandem MS (LC-MS/MS) method and performed plasma drug concentration measurements and monitoring using clinical laboratory values for both RUX and PCZ. We also compared our technique to a simple LC-MS/MS method for clinical application. Moreover, the utility of the automated pretreatment LC-MS/MS (auto-LC-MS/MS) method was tested for further applications. The simultaneous quantification LC-MS/MS method satisfied analytical validation criteria under clinical conditions. Our method demonstrated linearity over the range of 0.3-500 ng/mL for RUX and 3-5000 ng/mL for PCZ, with intra- and inter-day precision and accuracy within ±15%. A possible correlation between plasma RUX concentration and kidney injury was observed in 1 of the 6 patients. Notably, plasma PCZ concentrations were decreased by changing the administration route. Moreover, the plasma concentration levels obtained using the auto-LC-MS/MS method were highly concordant with those obtained using the LC-MS/MS method. The validated LC-MS/MS method was found to be useful in clinical applications; thus, further research into its applications in clinical practice is desirable.
-
Preventive Effects of Non-sedating and Sedating Histamine H1 Receptor Antagonists Premedication for Subcutaneous Daratumumab-Associated Infusion-Related Reactions: A Prospective Observational Study.
Mayu Yakumaru-Suzukawa, Tohru Aomori, Norifumi Suzuki, Koichi Ohata, Maiko Abumiya, Yukiyoshi Fujita, Tomoe Yoshizawa, Kaori Matsumoto, Akira Kudo, Naoya Suehiro, Shiori Hishida-Sadaka, Haruka Igarashi, Chinami Inoue, Tomoko Yamazaki, Junichiro Wakatsuki, Hiroomi Sakurai, Serika Banno-Matsuoka, Yayoi Fukushi, Hirotoshi Iihara, Masafumi Kikuchi, Hitoshi Kawazoe, Hisakazu Ohtani
Biological & pharmaceutical bulletin 49 ( 7 ) 1153 - 1160 2026 [Refereed]
Research paper (journal)
The optimal choice between sedating histamine H1 antagonists (sAHs) and non-sedating histamine H1 antagonists (nsAHs) for preventing infusion-related reactions (IRRs) during daratumumab subcutaneous (DARA-SC) therapy remains unclear. Here, we aimed to compare the efficacy and safety of nsAH and sAH as premedication for DARA-SC therapy. Patients with multiple myeloma or light-chain amyloidosis who received DARA-SC therapy at eight hospitals were enrolled in this prospective, multicenter, observational study. Patients were categorized into nsAH and sAH groups based on their premedication. IRRs and drowsiness were assessed using patient-reported questionnaires, including the Stanford Sleepiness Scale (SSS) and the Japanese Epworth Sleepiness Scale (JESS), at baseline, post-administration (Q2), and before bedtime (Q3). Overall, 104 patients (nsAH, n = 49; sAH, n = 55) were analyzed. No significant differences were observed in the IRR incidence between the nsAH and sAH groups at Q2 (8.2 vs. 9.1%) or Q3 (13 vs. 17%). Conversely, the incidence of new-onset drowsiness at Q2 was significantly lower in the nsAH group (13%) than in the sAH group (32%, p < 0.05). Additionally, the increase in SSS from baseline to Q2 was significantly lower in the nsAH group than in the sAH group (p < 0.05). No significant differences were observed in JESS scores. Thus, nsAH was associated with reduced early post-administration drowsiness and there were no statistically significant differences in IRR preventive effects compared to that for sAH, suggesting that nsAH may reduce sedation without a significant increase in the incidence of IRRs; however, these hypothesis-generating findings warrant verification through future prospective comparative trials.
-
Simultaneous analysis of remdesivir, favipiravir, and etoposide used to treat COVID-19 infection using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring
高崎新也, 佐藤稔之, 鈴木博也, 青柳哲史, 青柳哲史, 森下啓, 千葉僚, 佐藤裕, 佐藤紀宏, 菊地正史, 大島謙吾, 徳田浩一, 前川正充, 眞野成康
JSBMS Letters 46 ( Supplement ) 2021
-
Fundamental study for the development of LC/ESI-MS/MS method for simultaneous quantification of oral molecular targeted drugs and their metabolites
平澤天晴, 菊地正史, 菊地正史, 高崎新也, 公文代將希, 佐藤裕, 佐藤紀宏, 前川正充, 前川正充, 眞野成康, 眞野成康
JSBMS Letters 46 ( Supplement ) 2021
-
インソースCIDを利用したLC/ESI‐MS/MSによる薬物一斉定量法構築への取り組み
菊地正史, 前川正充, 塚本多矩, 眞野成康, 眞野成康
臨床化学 48 ( Suppl.1 ) 162 - 162 2019.08
-
インソースCIDを利用したLC/ESI‐MS/MSによる抗がん薬の同時測定法の構築に向けた基礎的検討
平澤天晴, 重田健介, 前川正充, 小倉次郎, 菊地正史, 菊地正史, 眞野成康, 眞野成康
臨床化学 ( (一社)日本臨床化学会 ) 48 ( Suppl.1 ) 251 - 251 2019.08
-
第2回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線〜分子標的探索と個別化医療への挑戦〜 経口分子標的薬の個別化投与設計に向けて
山口 浩明, 高崎 新也, 菊地 正史, 川崎 芳英, 荒井 陽一, 眞野 成康
薬学雑誌 ( (公社)日本薬学会 ) 139 ( 6 ) 911 - 915 2019.06
異なるチロシンキナーゼ阻害薬を服用している腎癌患者の血中濃度を,それぞれの最適条件で同時分析することは困難であり,これまでは各薬物を個別に測定する必要があった.チロシンキナーゼ阻害薬一斉測定法を開発したので概説した.さらに,日本人の腎細胞癌患者におけるスニチニブの有効血中濃度域を明らかにするため,総血中濃度と有害事象および治療継続期間の関連性について解析した.
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2021.04 - 2024.03
-
Grant-in-Aid for Encouragement of Scientists
Project Year： 2014.04 - 2015.03
-
Grant-in-Aid for Encouragement of Scientists
Project Year： 2013.04 - 2014.03
-
Grant-in-Aid for Encouragement of Scientists
Project Year： 2006 - 2006
Presentations 【 display / non-display 】
-
Fundamental study for the development of LC/ESI-MS/MS method for simultaneous quantification of oral molecular targeted drugs and their metabolites
平澤天晴, 菊地正史, 菊地正史, 高崎新也, 公文代將希, 佐藤裕, 佐藤紀宏, 前川正充, 前川正充, 眞野成康, 眞野成康
JSBMS Letters 2021 - 2021
-
Simultaneous analysis of remdesivir, favipiravir, and etoposide used to treat COVID-19 infection using liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring
高崎新也, 佐藤稔之, 鈴木博也, 青柳哲史, 青柳哲史, 森下啓, 千葉僚, 佐藤裕, 佐藤紀宏, 菊地正史, 大島謙吾, 徳田浩一, 前川正充, 眞野成康
JSBMS Letters 2021 - 2021
-
インソースCIDを利用したLC/ESI‐MS/MSによる抗がん薬の同時測定法の構築に向けた基礎的検討
平澤天晴, 重田健介, 前川正充, 小倉次郎, 菊地正史, 菊地正史, 眞野成康, 眞野成康
臨床化学 2019.08 - 2019.08 (一社)日本臨床化学会
-
血中エベロリムス濃度と臨床効果の関連性~腎癌治療における長期追跡調査~
高崎新也, 川崎芳英, 菊地正史, 田中雅樹, 山口浩明, 伊藤明宏, 眞野成康
TDM研究 2019.05 - 2019.05 (一社)日本TDM学会
Academic Activity 【 display / non-display 】
-
2026.07-Now
-
2026.07-Now
-
2026.07-Now
-
2026.04-Now
-
2026.04-Now